Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.4, replacing Revision: v3.5.3. This indicates a newer version of the study record.
    Difference
    0.0%
    Check dated 2026-05-17T10:07:06.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page’s displayed release/version marker was updated from “Revision: v3.5.2” to “Revision: v3.5.3” without changing the study information shown.
    Difference
    0.0%
    Check dated 2026-04-25T18:38:19.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Revision updated: v3.5.2 added; v3.5.0 removed.
    Difference
    0.0%
    Check dated 2026-04-18T13:30:26.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Added thyroid gland undifferentiated (anaplastic) carcinoma and small cell lung carcinoma to the study's listed conditions.
    Difference
    0.1%
    Check dated 2026-03-27T23:28:57.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    - Revision: v3.5.0 updated from v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-20T19:55:54.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Footer revision updated from v3.4.2 to v3.4.3. The change is cosmetic and does not alter content or functionality of the page.
    Difference
    0.0%
    Check dated 2026-03-06T18:00:12.000Z thumbnail image

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.